Cairo-Mubasher: DBK Pharmaceutical will delay its IPO due to the sell-off in the Egyptian market.

The subscription period was delayed from 17 August 2015 until 23 August 2015.

Earlier, the company's board approved the launch of a private placement for 37.29 million shares, or 25% of capital, as well as an initial public offering for 1.4 million shares, or 10% of capital, on the Egyptian Exchange.

The company’s board set the price for the private placement and the IPO at EGP 3.25 per share.